The brand is supported by a proprietary drug discovery platform, which enables the identification of novel mechanisms-of-action, targets, and first-in-class small molecules. reMYND's flagship program, ReS19-T, is an investigational compound specifically designed for the treatment of Alzheimer's. This program, which is poised to enter Phase 2a, has demonstrated promising results in animal models by restoring synaptic plasticity, a crucial process associated with the disease cascade leading to neuronal decline and the formation of plaques and tangles.

Additionally, reMYND's Huntington program has shown remarkable potential in fully restoring cortico-striatal transmission and regenerating the mouse brain in standard Huntington knock-in mice. Furthermore, reMYND leverages its innovative discovery platform to explore other treatments for central nervous system disorders, with a particular focus on mitochondrial dysfunction. In addition to its development programs, reMYND operates a dedicated Contract Research Organization (CRO) that assists clients in assessing the pharmacokinetics, pharmacodynamics, and efficacy of their experimental treatments using reMYND's proprietary animal models.

The CRO's wide-ranging client base spans across the globe. With a passionate team at the forefront of groundbreaking research, reMYND is committed to advancing therapeutic solutions to address major health challenges and improve the lives of patients worldwide